Navigation Links
Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Date:10/15/2007

ng statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) announced ... post-approval study of its NeuRx DPS® System for ... the FDA enrollment requirement was implanted over a ... NeuRx DPS®, which is the only medical device ... is a humanitarian device that obtained approval at ...
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE SUMMARY ... Industry Outlook to 2017 - Increasing Demand from ... analysis of the industry past, present and future ... Canada market with outlook to ... dietary supplements. Additionally the sub-segments of the industry, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
... 2011 Varian Medical Systems (NYSE: ... order from U.S. Customs and Border Protection (CBP) for multiple ... represents the company,s largest single order for Varian,s IntellX gantry ... border, scanning vehicles for both border security and manifest verification ...
... PITTSBURGH, Jan. 27, 2011 Mylan Inc. (Nasdaq: ... subsidiary Matrix Laboratories Limited has signed an agreement ... manufacture, market and distribute a generic version of ... pending its regulatory approval for the treatment of ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2Mylan's Matrix Obtains License for Promising HIV/AIDS Treatment 2
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Edward D. Buckingham, M.D., owner of ... approved to be a director of a fellowship for ... (AAFPRS) fellowship program. The announcement came last week from ... The Educational and Research Foundation for the AAFPRS fellowship ... the finest postgraduate program in the world for the ...
(Date:9/30/2014)... Gummy teeth treatment expert, Dr. ... dark gums. Dark gums are usually considered a cosmetic ... about their smiles. Dr. Farnoosh has pioneered a procedure ... of the few dental professionals nationwide offering black ... leaders, high-ranking officials and patients from all over the ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... supplements won,t prevent the return of a common type of ... In fact, 64.1 percent of those taking fish oil for ... over the course of 16 months, compared to 63.2 ... did not reduce the twin ills of inflammation or oxidative ...
(Date:9/30/2014)... 30, 2014 Lea Blackwell, M.D., a ... cancer patients a new, more practical and comfortable option ... undergo mastectomies, biopsies and lumpectomy surgeries use special bras ... after seeing her patients describe the bra as scratchy, ... a new bra in her spare time. , ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3
... many as 10% of people of Asian descent, operations ... mathematical models that verified the cost effectiveness of hepatitis ... vaccinate millions of Asian and Pacific Islander adults in ... to a paper in a journal of the Institute ...
... (HealthDay News) -- In the days after they start ... bupropion or venlafaxine, nursing home residents are at significantly ... Researchers found the increased risk for falls also ... their current prescription. "Our results identify the days ...
... increasing globally. Requiring two doctors to agree that a ... baby, rather than just needing one opinion, providing internal ... and seeking support from local opinion leaders may reduce ... relaxation classes for women with a fear or anxiety ...
... spoils of war for returning veterans may include addictions, ... witnessed. Now a University of Houston joint study ... Development service looks to address these issues through the ... College of Social Work (GCSW) joins Baylor College of ...
... News) -- Depression rates are higher in richer countries ... who compared socioeconomic conditions with depression. About 121 ... quality of life by affecting their ability to ... suicide and causes 850,000 deaths every year. Detailed ...
... 26 (HealthDay News) -- A person,s brain works hard to ... people,s shoes, no matter how different they may be, a ... California found people automatically attempt to empathize -- even with ... people must use two separate regions of their brain. ...
Cached Medicine News:Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 2Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 3Health News:Certain Antidepressants Linked to Falls in Nursing Homes 2Health News:Local efforts can stem the increasing unnecessary cesarean sections 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Depression Higher in Wealthier Nations 2Health News:Human Brains Wired to Empathize, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: